Prostate cancer is the second most common cancer among men worldwide, making it a significant health concern that should not be overlooked. While many may feel uncomfortable discussing or undergoing screenings for prostate cancer, early detection can be a lifesaver. This is where educational videos come into play, to shed light on the importance of annual prostate tests and encourage men to prioritize their health. NucleoBio, a leading biotech company, has taken a groundbreaking approach to prostate cancer diagnosis with the development of a molecular blood-based test. This innovative test provides early and precise results, enabling healthcare providers to recommend personalized interventions tailored to each individual's needs, potentially leading to life-saving outcomes. To amp up awareness and education around the significance of annual prostate tests, NucleoBio is leveraging engaging videos to demonstrate the simplicity of taking a blood test and receiving the results. These videos aim to demystify the process, showcase its ease, and emphasize the potential life-saving benefits that come with early detection. By utilizing videos as an educational tool, NucleoBio is not only promoting the importance of annual prostate tests but also empowering men to take control of their health. The visual medium of videos has proven to be an effective way to convey information and evoke emotions, making it a powerful tool in spreading awareness about proactive health measures. In conclusion, annual prostate tests play a crucial role in the early detection and treatment of prostate cancer. With the help of innovative companies like NucleoBio and their educational videos, more men can be encouraged to prioritize their health and take the necessary steps towards early detection and potentially life-saving interventions. Remember, your health is your wealth - make sure to prioritize it.

Prostate cancer is one of the most common cancers among men, with early detection being crucial for successful treatment. NucleoBio, a cutting-edge biotech company, has developed a revolutionary blood-based test that aims to change the landscape of prostate cancer diagnosis. This groundbreaking test offers precision diagnosis, empowering physicians to tailor personalized interventions for their patients. Traditionally, prostate cancer diagnosis involved invasive procedures that could be uncomfortable and daunting for many men. However, with NucleoBio's simple molecular test, the process has been streamlined into a quick and easy blood test. This empowers men to take control of their health and proactively monitor their prostate health with minimal hassle. One of the key advantages of NucleoBio's test is its ability to detect prostate cancer at an early stage. Early detection significantly increases the chances of successful treatment and better outcomes for patients. By emphasizing the importance of annual prostate testing, NucleoBio aims to raise awareness and encourage men to prioritize their health. In addition to providing a user-friendly testing process, NucleoBio's test also offers fast and accurate results. Gone are the days of waiting anxiously for weeks to receive a diagnosis. With this innovative test, patients can quickly obtain their results, enabling prompt decision-making and timely intervention if needed. To further support men in taking charge of their health, NucleoBio plans to utilize engaging video content to demonstrate the simplicity of the testing process. By leveraging digital platforms, the company aims to educate and empower men to prioritize their prostate health and undergo regular screenings. In conclusion, NucleoBio's commitment to advancing prostate cancer diagnosis through innovative technology is a game-changer in the healthcare industry. By offering a simple, precise, and efficient test, the company is revolutionizing the way prostate cancer is detected and treated. With early detection and personalized interventions, NucleoBio is not only saving lives but also empowering men to make informed decisions about their health.

We’re losing too many Black men to prostate cancer First Published in Rollout Magazine 1/12/2024 By Mr. Digital Fingers Jan 12, 2024 10:32 am Prostate health stands as a cornerstone of overall well-being, with particular importance for Black men who can significantly benefit from understanding their father’s health history. This article delves into the pivotal role that familial medical backgrounds play in shaping a proactive approach to individual health, specifically focusing on prostate health. By unraveling the intricate tapestry of family history, Black men gain invaluable insights into potential genetic predispositions and environmental factors that may impact their prostate health. The essence of this exploration lies in recognizing why comprehending family history is more than a retrospective glance—it’s a forward-looking strategy. Through this understanding, individuals can adopt preventive measures that extend beyond themselves, influencing the trajectory of their own health and that of future generations. Join us as we navigate the significance of family health legacies, shedding light on the proactive steps Black men can take to safeguard their well-being and contribute to a healthier tomorrow. The importance of family history At the heart of proactive health care lies a comprehensive understanding of family history. For Black men, this knowledge can offer valuable insights into potential health risks, particularly concerning prostate health. Family history serves as a road map, highlighting the genetic and environmental factors that might contribute to specific health conditions, including prostate-related issues. Why Black men should know their father’s history 1. Genetic predisposition Black men are known to have a higher risk of developing prostate cancer compared to other ethnic groups. Knowing your father’s health history allows for a better understanding of the genetic factors that may contribute to this increased risk. If there’s a history of prostate issues, it becomes even more crucial to be vigilant about regular checkups and screenings. 2. Early detection Prostate cancer, like many other forms of cancer, is more effectively treated when detected early. By familiarizing oneself with the health challenges that previous generations — especially fathers — have faced, Black men can be more attuned to potential warning signs. Regular screenings, starting at an age recommended by health care professionals, become paramount for early detection and intervention. 3. Lifestyle modifications A family’s health history not only provides insights into genetic factors but also sheds light on shared lifestyle choices and environmental exposures. Understanding these aspects can empower Black men to make informed decisions about their lifestyles, implementing changes that may reduce the risk of prostate issues. 4. Breaking the silence In many communities, discussions about health — especially sensitive topics like prostate health — can be limited. Knowing your father’s history can break the silence surrounding these issues, fostering open conversations about health within families. This, in turn, can encourage a more proactive approach to health care, emphasizing the importance of regular checkups and preventive measures. 5. Creating a health legacy By understanding their father’s health journey, Black men can actively contribute to creating a positive health legacy for future generations. Knowledge about family health history allows individuals to adopt a preventive mindset, influencing not only their well-being but also that of their children and grandchildren. The profound significance of delving into one’s father’s health history reverberates prominently, particularly in the realm of prostate health for Black men. This familial insight emerges as a potent tool encompassing early detection capabilities, heightened genetic awareness and a catalyst for essential lifestyle modifications. Beyond these tangible benefits, it becomes a pivotal force in dismantling the entrenched silence surrounding sensitive health issues prevalent in many communities. This story was created using AI technology.

SAN ANTONIO, Texas--(BUSINESS WIRE)--NucleoBio, Corp., a leading biotechnology innovator in precision oncology diagnostics, and PreCheck Health Services, a high-complexity CLIA-certified and CAP-accredited clinical laboratory, today announced a strategic collaboration to support clinical development and processing of the proprietary Prostac™ assay. This partnership aims to enable future application of the test across a broader clinical setting, supporting ongoing research and validation efforts for early detection and risk stratification in prostate cancer. The collaboration will leverage PreCheck’s advanced laboratory infrastructure and operational expertise to further validate and process Prostac™—a qPCR-based composite assay developed by NucleoBio to assess expression levels of specific long non-coding RNA biomarkers derived from the PVT1 gene. Prostac™: A Novel Biomarker-Based Composite Score At the core of this collaboration is Prostac™, a composite diagnostic score derived from the quantification of PVT1 exons 4A, 4B, and 9. These specific exons are significantly overexpressed in prostate cancer tissue in men of African ancestry and have demonstrated high accuracy in both preclinical and clinical models for distinguishing malignant from non-malignant samples. Prostac™ integrates the measured expression levels using supervised machine learning techniques—specifically, support vector classifiers—to generate a score that accurately predicts the likelihood of prostate cancer. The assay has shown promising early results, with 100% sensitivity and specificity in preliminary in vitro evaluations using prostate epithelial and prostate cancer cell lines. “Combining novel molecular markers with mathematical oncology through machine learning allows for robust and scalable diagnostic solutions,” stated Dr. Olorunseun Ogunwobi, co-developer of Prostac™ and co-founder of NucleoBio. “The ability to accurately identify early and aggressive cases of prostate cancer—non-invasively—represents a paradigm shift.” “The process of moving scientific findings or innovations from research institutions into the commercial sector and generating social impact is the main goal of any tech transfer,” says Neeti Mitra, Associate Director, CUNY Technology Commercialization Office, from where the core technology was licensed. “The vision of CUNY and NucleoBio was same from the beginning; to turn cutting edge research into market-ready products. Hence, we are excited about this collaboration between NucleoBio and Precheck Health Services.” Enabling Scalable, CLIA-Compliant Processing PreCheck Health Services will serve as the exclusive laboratory processing facility for clinical samples analyzed using the Prostac™ assay during its validation phase. Leveraging PreCheck’s robust genetic testing platform and automation infrastructure, this collaboration ensures consistency, compliance, and scalability under CLIA and CAP regulations. “As a clinical lab focused on precision medicine, we are proud to support a next-generation assay like Prostac™,” said Francis Pittilloni, Chief Operating Officer at PreCheck Health Services. “This initiative exemplifies our mission to bring forward validated, clinically actionable genetic tests that meet the highest standards of scientific and operational integrity.” The assay will initially be utilized for research use only (RUO) and early validation studies. Both companies affirm their commitment to maintaining full compliance with FDA and CMS guidelines concerning laboratory-developed tests (LDTs), including appropriate use disclosures. Addressing a Critical Clinical Gap Prostate cancer remains the most diagnosed solid tumor among men globally, with significant racial disparities in incidence and mortality. While PSA testing remains the current standard, its limitations—high false-positive rates, lack of specificity, and poor predictive value—have underscored the need for new biomarkers. “This is improved medical care,” says Neeti Mitra, Associate Director CUNY TCO, “transferring medical technologies like this with the future goal of bringing good quality healthcare to remote areas, reducing mortality and improving well-being. It will revolutionize treatment, making healthcare more personalized and accessible.” According to studies published in Frontiers in Oncology, PLOS ONE, and Genes, the PVT1 locus, particularly exon 9, plays a key oncogenic role in the initiation and progression of prostate cancer. Its upregulation correlates with castration resistance, increased cell proliferation, and poor prognosis. The Prostac™ composite score is being developed to address this unmet need—offering clinicians a more precise and biologically relevant indicator of disease activity, with the potential to reduce unnecessary biopsies and enhance early intervention. About NucleoBio, Corp. NucleoBio is a translational biotechnology company that spun out of Hunter College of The City University of New York (CUNY). Focused on addressing cancer health, NucleoBio develops RNA-based assays and molecular diagnostics derived from peer-reviewed research, including pioneering work on the PVT1 gene and its application in prostate cancer. NucleoBio’s core technologies are built on the foundation of validated molecular biology and machine learning models that support precision oncology. About PreCheck Health Services PreCheck Health Services is a CAP-accredited, CLIA-certified high-complexity laboratory specializing in advanced molecular testing for oncology, pharmacogenetics, and neurogenetics. Serving providers nationwide, PreCheck combines rigorous scientific standards with cutting-edge automation, offering scalable, compliant, and clinically relevant diagnostic services that support personalized care and medical innovation. About CUNY The City University of New York is the nation’s largest urban public university, a transformative engine of social mobility that is a critical component of the lifeblood of New York City. Founded in 1847 as the nation’s first free public institution of higher education, CUNY today has 26 colleges spread across New York City’s five boroughs, serving nearly 240,000 degree-seeking students of all ages and awarding 50,000 degrees each year. More than 80 percent of the University’s graduates stay in New York, contributing to all aspects of the city’s economic, civic and cultural life and diversifying the city’s workforce in every sector. The University’s historic mission continues to this day: provide a public first-rate education to all students, regardless of means or background. Forward Outlook Both parties plan to expand the clinical applications of the Prostac™ assay beyond the research phase, targeting broader clinical validation and potential inclusion in future clinical decision pathways. Further details regarding commercialization timelines and payer engagement will be announced following regulatory clearance and additional peer-reviewed studies. Contacts For more information or media inquiries: NucleoBio, Corp.Email: info@nucleobio.net Website: www.nucleobio.net

Prostate cancer is one of the most common forms of cancer that affect men globally. It is crucial to detect this cancer early to allow for effective treatment and a higher chance of survival. In recent years, a biotech company, NucleoBio, has made significant strides in the fight against prostate cancer with the development of a groundbreaking blood test. This blood test is a molecular-based diagnostic tool that enables the early and accurate detection of prostate cancer. Unlike traditional screening methods that can be invasive and uncomfortable, this test is non-invasive and only requires a simple blood draw. The results provide physicians with detailed information about the patient's cancer profile, allowing for personalized treatment plans to be tailored based on individual needs. One of the key benefits of this blood test is its ability to save lives by detecting prostate cancer in its early stages when it is most treatable. By catching the cancer early, patients have a better chance of successful treatment and survival. This is a game-changer in the fight against prostate cancer and has the potential to impact countless lives in a positive way. In an effort to raise awareness about the importance of regular prostate cancer screening, NucleoBio has created engaging videos demonstrating the simplicity of the blood test process. These videos aim to empower men to take charge of their health and prioritize regular prostate screenings as part of their healthcare routine. It is crucial for men to understand the significance of early detection in combating prostate cancer. By educating themselves about the available screening options, such as this innovative blood test from NucleoBio, men can take proactive steps towards protecting their health and well-being. Annual prostate screenings are essential for early detection, and this new blood test offers a convenient and effective way to stay ahead of the disease. In conclusion, the development of a blood-based test for early detection of prostate cancer is a major breakthrough in the field of oncology. By offering a non-invasive and accurate screening method, NucleoBio is revolutionizing how prostate cancer is diagnosed and treated. It is a testament to the power of innovation in saving lives and making a positive impact on global health.